Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8
Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8
Roth MKm維持對aptevo therapeutics的買入評級,將目標價調整至$8
Roth MKM analyst Jonathan Aschoff maintains Aptevo Therapeutics (NASDAQ:APVO) with a Buy and lowers the price target from $15 to $8.
Roth MKm分析師Jonathan Aschoff維持對aptevo therapeutics(納斯達克:APVO)的買入評級,將目標價從$15降至$8。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。